Albumedix now a part of Sartorius’ Post

In an industry where change is ever constant, Andelyn Biosciences stands as your steadfast partner in gene therapy manufacturing. With over two decades of experience and expertise, our commitment to growth and innovation ensures we're here for you, ready to bring your groundbreaking therapies from the lab to the patient. See what a feasibility study and yield assessment can do to get your program started on a path to process industrialization: https://buff.ly/3UzqzNP #andelynbiosciences

🧬Insightful article of our colleagues from Camelot Management Consultants about Pharma Logistics Challenge for Cell & Gene Therapies. 🧾Very worth reading! #hypertrust #CGT

12 Days of Cell Therapy 🎄 As we continue our countdown to the holidays, we’re spotlighting a new key advancement in the Cell and Gene Therapy sector from 2024. Day 2: The global iPSC market is growing rapidly and is expected to reach $4.8 billion by 2030, with a compound annual growth rate (CAGR) of 8.5%. This impressive growth reflects the increasing demand for iPSCs in regenerative medicine and drug development, signalling a bright future for this innovative technology. Source: https://hubs.la/Q02_0__Q0 #12daysofcelltherapy #celltherapy #genetherapy #advancedtherapies #12daysofchristmas

  🌐Overcoming Pharma Logistics Challenges, Particularly for Cell & Gene Therapies   Cell and Gene Therapies (CGTs) promise personalized treatments but bring significant logistical hurdles. Key challenges include regulatory delays, the need for specialized partners, limited visibility, scalability issues, and unforeseen disruptions.⚡️   At Camelot, we offer strategies to navigate these complexities in pharma logistics, ensuring timely and safe delivery of therapies to patients. Curious about how to tackle these challenges? Read our full blog post to learn more! 🚀   🔗 To the article: https://lnkd.in/etsmYjMW   #PharmaLogistics #CGT #SupplyChain #LifeSciences #Innovation 

During the recent Reuters Pharma USA conference, Lung I-Cheng, VP of cell and gene therapy, had a chance to talk to pharmaphorum about the evolution of CGT, current momentum, and standardization across the industry. Watch the discussion: https://ow.ly/tNR350RsUby

Delving into Cell and Gene Therapy (CGT), the role of Chemistry, Manufacturing, and Controls (CMC) is crucial, particularly in exosome development. But what exactly does CMC entail for exosomes? This blog explores the intricate landscape of early-stage CMC considerations for exosomes in drug development, shedding light on key considerations for IND applications and providing recommendations that pave the way for the development of these innovative products. For more for insights, read our blog, "Cell and Gene Therapy Advancements: Early-Stage CMC Strategies for Exosomes Innovation". https://lnkd.in/g9xCt3pe #Allucent #BringNewTherapiesToLight #CMC #RegulatoryAffairs #CellandGeneTherapy #Exosomes 

📢 Don't miss tomorrow's Cell & Gene Therapy Insights’ webinar on unlocking success in CAR T tech transfer, featuring expert panelists, Sara Mills at Dark Horse Consulting Group Inc., Neil Blackburn at OmniaBio, and Dan Miskimin at BrainChild Bio.    Register today: https://lnkd.in/gJbqp7T9 Key topics:   ➡️ Discuss typical obstacles encountered in tech transfer and how to proactively address them.  ➡️ Discover how to master the CAR T cell therapy tech transfer process.  ➡️ Learn from a real-world case study showing how to achieve seamless transition to GMP manufacturing. #CellandGeneTherapy #CellTherapy #GeneTherapy #Webinar 

Meet the Sannova team at The American Society of Gene & Cell Therapy (ASGCT) annual meeting, booth # 2048. Conference highlights: ✅Cutting-edge Research ✅Networking Opportunities ✅Professional Development Discover new tools, technologies, and resources essential for advancing your work. Stay up-to-date with industry trends, regulations, and potential future directions in cell and gene therapy. Going to ASGCT2024? Introduce yourself in the comments. #biotech, #immunotherapy, #ASGCT2024 #genetherapy #celltherapy

American Red Cross Cell and Gene Therapy Solutions understands how important it is to minimize variability that can impact cell therapy manufacturing processes. Our approach to reducing variability helps minimize raw material challenges: ✅All collection sites operate under a single National Quality Management System (QMS) ✅Standardized collection procedures and equipment across our seven collection sites with national SOPs ✅All collections adhere to good tissue practices ✅ Flexibility to implement new protocols and adjust collection parameters across sites while meeting custom collection protocols We work with you to understand how donor attributes and apheresis practices could impact your manufacturing applications and patient outcomes. Red Cross Cell and Gene Therapy Solutions can support your therapy from discovery to end-stage development – learn more. Feel free to send me a message if you'd like to connect or visit our site for more information: https://lnkd.in/gxRDx6sm #GeneTherapy, #CellTherapy, #BioTherapy

Come join Senthil Ramaswamy and I as we discuss the critical needs for the future of Cell and Gene Therapies